Tyrphostin 4-nitrobenzylidene malononitrile reduces chemotherapy toxicity without impairing efficacy

Cancer Research

Volumn 58, Issue 11, 1998, Pages 2397-2403

  Novogrodsky, Abraham ^a,b   Weisspapir, Michael ^a,b   Patya, Miriam ^a,b   Meshorer, Asher ^c   Vanichkin, Alexey ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROBENZYLIDENE MALONONITRILE; CISPLATIN; CREATININE; DOXORUBICIN; NITROGEN; TYRPHOSTIN; UNCLASSIFIED DRUG; UREA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; COLONY FORMING UNIT; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; INTESTINE INJURY; INTRAPERITONEAL DRUG ADMINISTRATION; MORTALITY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 0032101139     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hoagland, H. C. Hematological complications of cancer chemotherapy. In: M. C. Perry (ed.), The Chemotherapy Source Book, pp. 498-507. Baltimore: Williams and Wilkins, 1992.
2. Mitchel, E. P., and Schein, P. S. Gastrointestinal toxicity of chemotherapeutic agents. In: M. C. Perry (ed.), The Chemotherapy Source Book, pp. 620-634. Baltimore: Williams and Wilkins, 1992.
3. McInnes, S., and Schilsky, R. L. Infertility following cancer chemotherapy. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, Ed. 2, pp. 31-44. Philadelphia: Lippincott-Raven Publishers, 1996.
4. Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L., Jr., Von Hoff, A. L., Rozencweig, M., and Muggia, E. M. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med., 91: 710-717, 1979.
5. Blachley, J. D., and Hill, J. B. Renal and electrolyte disturbances associated with cisplatin. Ann. Intern. Med., 95: 628-632, 1981.
6. Comis, R. L. Bleomycin pulmonary toxicity: current status and future directions. Semin. Oncol., 19: 64-70, 1992.
7. Skinner, R., Sharkey, I. M., Pearson, A. D. J., and Craft, A. W. Ifosfamide, MESNA and nephrotoxicity in children. J. Clin. Oncol., 11: 173-190, 1993.
8. Capizzi, R. Amifostin: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin. Oncol., 23: 2-17, 1996.
9. Herman, E. H., and Ferrans, V. J. Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced cardiomyopathy. Cancer Treat. Rev., 17: 155-160, 1990.
10. Siveski-Iliskovic, N., Hill, M., Chow, D. A., and Singal, P. K. Probucol protects against Adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation, 91: 10-15, 1995.
11. McVie, J. G. The role of pharmacokinetics in (combination) chemotherapy. Cancer (Phila.), 54: 1175-1178, 1984.
12. Carlson, R. W. Continuous intravenous infusion chemotherapy. In: M. C. Perry (ed.), The Chemotherapy Source Book, pp. 232-255. Baltimore: Williams and Wilkins, 1992.
13. Gabrilove, J. L. Colony stimulating factors: clinical status. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 445-463. Philadelphia: J. B. Lippincott Company, 1991.
14. Barry, M. A., Behuke, C. A., and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxin and hyperthermia. Biochem. Pharmacol., 40: 2353-2362, 1990.
15. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Apoptosis, its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
16. Searle, J., Lawson, T. A., Abbot, P. J., Harmon, B., and Kerr, J. F. R. An electronmicroscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J. Pathol., 116: 129-138, 1975.
17. Thakker, N. S., and Potten, C. S. Inhibition of doxorubicin-induced apoptosis in vivo by 2-deoxy-D-glucosc. Cancer Res., 53: 2057-2060, 1993.
18. Lieberthal, W., Triaca, V., and Levine, J. Mechanism of death induced by cisplatin in proximal tumular epithelial cells: apoptosis versus necrosis. Am. J. Physiol., 270: F700-F708, 1996.
19. Onishi, Y., Azuma, Y., Sato, Y., Mizuno, Y., and Tadakuma, T. Topoisomerase inhibitors induce apoptosis in thymocytcs. Biochim. Biophys. Acta, 1175: 147-154, 1993.
20. Ji, L., Zhang, G., and Hirabayashi, Y. Inhibition of tumor necrosis α- and ceramide-induced internucleosomal DNA fragmentation by herbimycin A in U937 cells. Biochem. Biophys. Res. Commun., 212: 640-647, 1995.
21. Liu, Y., Bhalla, K., Hill, C., and Priest, D. G. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in human ovarian tumor cell line. Biochem. Pharmacol., 48: 1265-1272, 1994.
22. Uckun, F. M., Tuel-Ahlgren, L., Song, C. W., Waddick, K., Myers, D. E., Kirihara, J., Ledbetter, J. A., and Schieven, G. L. Ionizing radiation stimulates unidentified tyrosine-specific protein kinases in human B-lymphocyte precursors, triggering apoptosis and clonogenic cell death. Proc. Natl. Acad. Sci. USA, 89: 9005-9009, 1992.
23. Bergamaschi, G., Rosti, V., Danova, M., Ponchio, L., Lucotti, C., and Cazzola, M. Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines. Leukemia (Baltimore), 7: 2012-2018, 1993.
24. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
25. Sturz, H. G., and Noller, C. R. Some substituted benzalmalononitriles. J. Am. Chem. Soc., 71: 2949, 1949.
26. Nikerich, D. A., Young, M. R., Ellis, N. K., Newby, M., and Wepsic, H. T. Stimulation of hematopoiesis in untreated and cyclophosphamide treated mice by inhibition of prostaglandin synthesis. J. Immunopharmacol., 8: 299-313, 1986.
27. Gal, E. M., Fung, F-H., and Greenberg, D. M. Studies on the biological action of malononitriles. I. The effect of substituted malononitriles on the growth of transplanted tumors in mice. Cancer Res., 12: 565-572, 1952.
28. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugal, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. Lethal effect of the anti-fas antibody in mice. Nature (Lond.), 364: 806-809, 1993.
29. Friesen, C., Herr, I., Krammer, P. H., and Debatin. K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.